Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hMAB IL-6 trans-signalling
- Development stage
- Preclinical
- Lead developer
- MAB DESIGNS
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
hMAB IL-6 trans-signalling (C20) is a preclinical humanized IgG1 monoclonal antibody being developed by MAB Designs. It selectively blocks interleukin-6 (IL-6) trans-signaling (mediated by the soluble IL-6 receptor) without affecting IL-6 classical signaling. This selective mechanism of action distinguishes it from currently approved IL-6 antibodies, which block both pathways and are associated with broader immunosuppressive side effects. By targeting only the pro-inflammatory trans-signaling arm, the drug aims to expand the therapeutic utility of IL-6 inhibition into indications such as central nervous system (CNS) disorders, oncology, systemic diseases, and ophthalmology.
- Other names
- hMAB IL-6 transignalling
02
Targets
IL-6 (Interleukin 6)IL-6R (Interleukin-6 receptor subunit alpha)IL6ST (Interleukin-6 receptor subunit beta)
Beyond the preview
Go deeper on hMAB IL-6 trans-signalling.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hMAB IL-6 trans-signalling.